Lymphoproliferative Disorders – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Lymphoproliferative Disorders – Drugs In Development, 2024 report and make more profitable business decisions.
Lymphoproliferative disorders (LPD) constitute a diverse group of diseases marked by uncontrolled lymphocyte production, resulting in monoclonal lymphocytosis, lymphadenopathy, and bone marrow infiltration. Predominantly affecting immunocompromised individuals, these disorders involve two subsets of lymphocytes, T and B cells, leading to immunoproliferative disorders with inherent risks of immunodeficiency and lymphocyte dysregulation. Causative gene mutations, whether iatrogenic or acquired, are identified through somatic or germ-line mutations in ALPS genes (FASL, CASP10, FAS), contributing to defective Fas-mediated apoptosis. Allogeneic hematopoietic stem cell transplantation often offers a cure, while specific treatments vary. Primary-EBV infection-associated hemophagocytic lymphohistiocytosis is managed with steroids, cyclosporine A, and etoposide.
The Lymphoproliferative Disorders drugs in development market research report provide comprehensive information on the therapeutics under development for Lymphoproliferative Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lymphoproliferative Disorders and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Lymphoproliferative Disorders | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 21 molecules, with 18 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Lymphoproliferative Disorders therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Lymphoproliferative Disorders pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Lymphoproliferative Disorders treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AB2 Bio LtdAffiliated Hospital of Xuzhou Medical University
AstraZeneca Plc
Atara Biotherapeutics Inc
Baylor College of Medicine
Beijing Boren Hospital
Biogen Inc
bluebird bio Inc
Bristol-Myers Squibb Co
Corvus Pharmaceuticals Inc
Grid Biosciences Hong Kong Ltd
Innovent Biologics Inc
Klyss Biotech Inc
Lion TCR Pte Ltd
Moderna Inc
Palvella Therapeutics LLC
Shanghai First Song Therapeutics Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Swedish Orphan Biovitrum AB
Tessa Therapeutics Ltd
Viracta Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Lymphoproliferative Disorders reports